Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Pass Below 200 Day Moving Average – Should You Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.65 and traded as low as $3.51. Cryo-Cell International shares last traded at $3.58, with a volume of 7,141 shares.

Cryo-Cell International Stock Performance

The company has a fifty day simple moving average of $3.40 and a two-hundred day simple moving average of $3.65. The stock has a market capitalization of $27.81 million, a price-to-earnings ratio of -10.45 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $7.68 million for the quarter.

Hedge Funds Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP acquired a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International as of its most recent SEC filing. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.